Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000817

Drug Information
NameNalidixic Acid
SynonymsUriclar; Acide nalidixique; LS-72; BSPBio_000113; Unaserus; nalidixic acid; Narigix; UNII-3B91HWA56M; SPBio_002034; SMR000058264; Nevigramon; Acido nalidixico; Nalidixinic acid; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; Sicmylon; AKOS000120074; Jicsron; 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure [German]; NINDS_000058; Poleon; KBio3_001109; CCRIS 2365; Eucistin; NCGC00021730-04; KBio2_006534; Urisal; naladixic acid; SPECTRUM1500756; NCGC00021730-03; CPD000058264; Oprea1_010545; N-1200; KBio2_001398; Nalidixate; Nalidixan; NegGram; Dixinal; SAM002554914; 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; HMS1921G10; KBio1_000058; Nalix; Nalidixic acid USP27; NCGC00021730-05; Acido nalidixico [INN-Spanish]; BIDD:GT0529; Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico [Italian]; Acide nalidixique [INN-French]; BSPBio_001889; KBioSS_001398; 1-Ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-carboxylic acid; SR-01000003086-4; Nalidixane; Specifin; D00183; Cybis; Wintron; Wintomylon; 5-25-07-00384 (Beilstein Handbook Reference); 1,4-Dihydro-1-ethyl-7-methyl-1,8-naphthyridin-4-one-3-carboxylic acid; 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxilic acid; WIN 18,320; Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico; Nalidixic acid [USAN:INN:BAN:JAN]; Uropan; 3-Carboxy-1-ethyl-7-methyl-1,8-naphthyridin-4-one; Dixiben; Nalidixic acid (JP15/USP/INN); Nogram; NCGC00021730-06; Nalitucsan; NCIOpen2_004342; Spectrum2_001360; 3-Carboxy-1-ethyl-7-methyl-1,8-naphthidin-4-one; HMS2092K04; BB_NC-2103; Acide nalidixique [French]; AC1Q310A; wil 18,320; Acido nalidissico; BRN 0750515; Nalurin; Lopac0_000837; Nicelate; STK735579; N5035_SIAL; BRD-K47886988-323-03-0; NCGC00018181-01; CHEMBL5; 3374-05-8 (hydrochloride salt, anhydrous); Acid, Nalidixic; Uroneg; Prestwick2_000187; VU0239598-6; CID4421; Negram; Nalidic acid; 389-08-2; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; UPCMLD-DP129:001; MLS001148578; 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure; Betaxina; Sodium Nalidixic Acid, Monohydrate; NegGram (TN); Uralgin; D009268; BPBio1_000125; Naxuril; Spectrum_000918; NCGC00021730-07; Specifen; WLN: T66 BN EV JNJ B2 DVQ I1; NCI-C56199; Naldixic acid; Acidum nalidixicum [INN-Latin]; MolPort-001-769-233; S2328_Selleck; HMS561K17; NSC82174; Prestwick3_000187; MLS002303041; 1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-1,4-dihydro-7-methyl-4-oxo-; Acido nalidissico [DCIT]; Acide nalidixico; N0490; N8878_SIAL; 1,4-Dihydro-1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; EINECS 206-864-7; Spectrum3_000075; DivK1c_000058; HMS500C20; AC1L1I4P; MLS000028504; Acidum nalidixicum; Kusnarin; Acide nalidixico [Italian]; WIN 183203; UPCMLD-DP129; Nalidixic; Prestwick1_000187; Uronidix; Sodium Nalidixic Acid, Anhydrous; NALIDIXATE SODIUM; Maybridge1_007101; DB00779; NCI60_041807; CHEBI:100147; Innoxalon; Prestwick0_000187; Urodixin; KBioGR_001333; C05079; HSDB 3241; InChI=1/C12H12N2O3/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14/h4-6H,3H2,1-2H3,(H,16,17; Uriben; Nalidixin; 1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; NSC-82174; Sodium, Nalidixate; Uroman; WIN-18320; Spectrum5_001540; Spectrum4_000817; SPBio_001579; KBio2_003966; 1-ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-ca rboxylic acid; ZERO/002632; IDI1_000058; Nalidicron
Trade NameNeggram; Wintomylon; WIN-18320
IndicationBacterial infections
[ICD9: 001-009, 010-018, 020-027, 030-041, 080-088, 090-099, 100-104   ICD10: A00-A09, A15-A19, A20-A28, A30-A49, A65-A69, A70-A74, A75-A79]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C12H12N2O3/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14/h4-
6H,3H2,1-2H3,(H,16,17)
InChIKeyMHWLWQUZZRMNGJ-UHFFFAOYSA-N
Canonical SMILESCCN1C=C(C(=O)C2=C1N=C(C=C2)C)C(=O)O    
Therapeutic ClassAnti-Bacterial Agents
CAS NumberCAS 389-08-2
FormulaC12H12N2O3
PubChem Compound IDCID 4421.
PubChem Substance IDSID 7525.
SuperDrug ATC IDJ01MB02
SuperDrug CAS ID000389082;
TargetDNA topoisomerase IIInhibitor[2]
Ref 1FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 071919 To Reference
Ref 2Activity of fluoroquinolone antibiotics against Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 1988 Aug;32(8):1182-6. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543